SuperworthSpyGlass Pharma EPS SGP
Diluted earnings per share by quarter and over the last twelve months, from 2025.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$0.59
SpyGlass Pharma's twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$0.59.
Earnings per share over time
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier |
|---|---|---|---|
| Q2 FY26 | −$0.59 | n/a | |
| Q1 FY26 | −$0.69 | n/a | |
| Q2 FY25 | −$3.81 | n/a | |
| Q1 FY25 | −$3.96 | n/a |
Against its peers
Companies in Medical - Instruments & Supplies nearest SpyGlass Pharma's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| SGPSpyGlass Pharma | n/m | |
| IRMDIradimed | $1.79 | +10% a year |
| STAAStaar Surgical | $0.07 | |
| BVSBioventus | $0.77 | |
| CDRECadre | $0.81 | −14% a year |
| MOVMovado | $1.80 | +137% a year |
| EYENational Vision | $0.61 | |
| MDXGMimedx | $0.04 | −81% a year |
| TCMDTactile Systems Technology | $1.08 | +74% a year |
| LMATLemaitre Vascular | $2.85 | +38% a year |
| INSPInspire Medical Systems | $4.62 | +166% a year |
| Peer median | $0.94 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on SpyGlass Pharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.